What is the role of trastuzumab deruxtecan in the treatment of gastric cancer?

Updated: Feb 23, 2021
  • Author: Elwyn C Cabebe, MD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print
Answer

The first HER2-directed antibody conjugate was approved by the FDA in January 2021. It is approved for locally advanced and metastatic HER2-positive gastric or GE junction adenocarcinoma in patients who were previously treated with a trastuzumab-based regimen.

Approval was based on the phase 2 DESTINY-Gastric01 trial, which randomized patients (n=187) to receive either trastuzumab deruxtecan or physician’s choice of chemotherapy. Objective response was higher in the trastuzumab deruxtecan group compared with the chemotherapy group (51% versus 14%). Overall survival was longer with trastuzumab deruxtecan than with chemotherapy (12.5 months versus 8.4 months). [60]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!